| Name | Title | Contact Details |
|---|---|---|
Kris Jamsa |
Chief Technology Officer | Profile |
Summus Global, the leading virtual specialist platform, empowers families by providing access to a network of 4,000+ top specialists across 48 leading hospitals -- within days, from anywhere in the world.
Delta Regional Medical Center has been committed to serving the citizens of Washington County and the outlying areas since our founding in the 1950s. Over time we have grown and progressed into a state-of-the-art hospital with a number of specialty
NovaMed, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
For more than 85 years, the Hendrick name has been the first name in healthcare in Abilene, Texas, and the Texas Midwest. As the first healthcare network to establish a true system of services, the Hendrick name reigns over a 522-bed medical center, a women’s center, rehabilitation hospital, cancer center and numerous other innovative services. Hendrick was the first hospital to permanently serve the Texas Midwest when its doors opened in 1924. During the Great Depression, it was the first hospital people of the Big Country area rallied behind to keep the doors open when money was scarce. Mr. and Mrs. Thomas Hendrick, for whom the institution was named, made the first major financial gift to the hospital. Through the years it has been the first in the area to offer specialized services, creating departments to fill needs such as physical medicine, nuclear medicine, spiritual care and much more.
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.